Under the quick to results category with Cancer in
Post# of 148126
1) Short life expectancy: at the time of diagnosis it is just 4.6 months. When I was getting my education this was an 3 month diagnosis…not much has changed. Only 3% of people diagnosed with pancreatic cancer will survive for 5 years. This implies the duration of the study could be reasonably short, with the potential during interim analysis resulting in a study halt for efficacy and related potential for approval.
2) We know pancreatic cancer is a high CCR5 expressing tumor, higher odds of success. Patients would be grateful that we could wrest control away from the grim reaper.
3) Unmet need…FDA fast track status.
This is not on Jay’s short list, I like his priorities…would be nice to partner for some of this stuff.